Auris Medical (NASDAQ:EARS) Trading 7.9% Higher

Shares of Auris Medical Holding Ltd (NASDAQ:EARS) traded up 7.9% during mid-day trading on Friday . The stock traded as high as $1.52 and last traded at $1.50, 390,200 shares were traded during trading. An increase of 158% from the average session volume of 151,135 shares. The stock had previously closed at $1.39.

Several equities analysts have issued reports on the company. Zacks Investment Research raised Auris Medical from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 22nd. ValuEngine raised Auris Medical from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd.

The stock has a fifty day moving average of $1.84 and a 200-day moving average of $2.64. The stock has a market cap of $2.64 million, a PE ratio of -0.10 and a beta of -0.51.

A hedge fund recently bought a new stake in Auris Medical stock. Jane Street Group LLC purchased a new position in shares of Auris Medical Holding Ltd (NASDAQ:EARS) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 10,934 shares of the biotechnology company’s stock, valued at approximately $30,000. Jane Street Group LLC owned about 0.58% of Auris Medical as of its most recent SEC filing. Hedge funds and other institutional investors own 9.59% of the company’s stock.

About Auris Medical (NASDAQ:EARS)

Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss.

Further Reading: Are FAANG stocks a good investment?

Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.